Want to see SE:QLIFE full AI Analyst Report?
QLIFE Stock Chart & Stats
kr3.01
-kr0.24(-7.59%)
At close: 4:00 PM EST
kr3.01
-kr0.24(-7.59%)
Day’s Range― - ―
52-Week Rangekr1.20 - kr4.62
Previous CloseN/A
Volume24.68K
Average Volume (3M)97.19K
Market Cap
kr53.30M
Enterprise Valuekr18.93
Total Cash (Recent Filing)kr6.63M
Total Debt (Recent Filing)kr8.71M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding28,874,178
10 Day Avg. Volume81,486
30 Day Avg. Volume97,188
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-126.16
Revenue Forecast (FY)kr116.00M
Bulls Say, Bears Say
Bulls Say
Near-patient Diagnostics PlatformA platform aimed at near-patient and home diagnostics can support recurring test adoption and digital follow-up over time, giving Qlife a potentially scalable model if it converts its technology into meaningful commercial demand.
Positive TTM Equity PositionThe return to positive trailing equity provides a modest balance-sheet improvement versus prior periods and offers a better capital base for operations, although the benefit remains limited by substantial debt and continuing losses.
Reported Revenue Growth IndicatorThe reported revenue-growth indicator suggests there has been a period of expansion in the company’s revenue base, which could support operating leverage if growth becomes consistent and reaches a scale capable of absorbing the current cost structure.
Bears Say
Very Small And Declining Revenue BaseMinimal and declining revenue indicates weak commercial traction and leaves the company highly exposed to execution risk. Without sustained sales growth, Qlife is unlikely to build the scale needed to support its diagnostics platform and fixed costs.
Deeply Negative ProfitabilityNegative gross profit and very large operating losses show that the current business model does not yet cover product and operating costs. Persistent losses could constrain investment, require financing, and delay any path to self-sustaining operations.
Cash Burn And High LeverageOngoing cash consumption combined with debt of roughly 4.6 times equity leaves limited financial flexibility. Unless revenue and margins improve materially, Qlife may remain dependent on external funding to sustain development and operations.
QLIFE FAQ
What was Qlife Holding AB’s price range in the past 12 months?
Qlife Holding AB lowest stock price was kr1.20 and its highest was kr4.62 in the past 12 months.
What is Qlife Holding AB’s market cap?
Qlife Holding AB’s market cap is kr53.30M.
When is Qlife Holding AB’s upcoming earnings report date?
Qlife Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 2 days.
How were Qlife Holding AB’s earnings last quarter?
Qlife Holding AB released its earnings results on May 13, 2026. The company reported -kr0.719 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Qlife Holding AB overvalued?
According to Wall Street analysts Qlife Holding AB’s price is currently Overvalued.
Does Qlife Holding AB pay dividends?
Qlife Holding AB does not currently pay dividends.
What is Qlife Holding AB’s EPS estimate?
Qlife Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlife Holding AB have?
Qlife Holding AB has 28,874,178 shares outstanding.
What happened to Qlife Holding AB’s price movement after its last earnings report?
Qlife Holding AB reported an EPS of -kr0.719 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.817%.
Which hedge fund is a major shareholder of Qlife Holding AB?
Currently, no hedge funds are holding shares in SE:QLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlife Holding AB
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.